Format

Send to

Choose Destination
Br J Haematol. 2019 Apr 1. doi: 10.1111/bjh.15888. [Epub ahead of print]

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.

Author information

1
Institut Gustave Roussy, Villejuif, France.
2
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
3
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA.
4
University of Cincinnati Cancer Institute, Cincinnati, OH.
5
Central Texas Veterans Affairs Health Care System, Temple, TX.
6
Center for Advanced Medicine, Washington University School of Medicine, St. Louis, MO.
7
Merck & Co., Inc., Kenilworth, NJ.
8
Hackensack University Medical Center, Hackensack, NJ.

KEYWORDS:

PD-1 (PDCD1); multiple myeloma; pembrolizumab

PMID:
30937889
DOI:
10.1111/bjh.15888

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center